Immune checkpoint blockade effect on immunologic and virologic profile of five cancer patients living with human immunodeficiency virus (HIV) infection.
Azzam YazjiErika Nicole BrownRodrigo De La TorreGodsfavour Oghenero UmoruPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
Immune checkpoint inhibitors may be efficacious and tolerable for treatment of cancer in patients living with HIV. Upward trends in CD4 + cell counts observed in this case series suggest that immune checkpoint inhibitors may enhance HIV disease control. Further research is needed for this patient population to supply more robust evidence for clinical practice.
Keyphrases
- human immunodeficiency virus
- antiretroviral therapy
- hiv infected
- hiv positive
- hepatitis c virus
- hiv aids
- end stage renal disease
- clinical practice
- ejection fraction
- newly diagnosed
- chronic kidney disease
- papillary thyroid
- peritoneal dialysis
- hiv testing
- case report
- bone marrow
- patient reported outcomes
- prognostic factors
- cell therapy
- mesenchymal stem cells
- combination therapy
- lymph node metastasis